Saturday, October 26, 2024
6:15 AM-7:15 AM ET
Division of Allergy, Pulmonary, and Critical Care Medicine
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee
University of Utah
Practicing Clinician
University Medical Center and Huntsman Cancer Institute
Salt Lake City, Utah
University of Utah School of Medicine
Associate Director, Pathology Residency Program
Medical Director, Hematopathology and Immunohistochemistry Laboratory
ARUP Laboratories, Inc.
Salt Lake City, Utah
The Non-CME Corporate Forum content and views expressed therein do not necessarily reflect the views, policies or position of the American College of Allergy, Asthma & Immunology.
There is no registration fee for attending this Non-CME Corporate Forum; however, seating is limited. Preregistration does not guarantee seating. We recommend arriving at the meeting room early.
Prefer to participate in person? Register at ExchangeCME.com/SMBostonLive.
Target Audience
The design of this activity addresses the needs of clinical immunologists, allergists, dermatologists, and other attendees of ACAAI who manage patients with nonadvanced systemic mastocytosis (SM).
Program Overview
Nonadvanced systemic mastocytosis (SM) is a difficult disorder to diagnose and manage due to the wide variety of symptoms, anaphylactic triggers, and a complicated individualized treatment paradigm. Join us for this engaging Expert Roundtable™ to hear multidisciplinary insights related to the diagnosis and treatment strategies for nonadvanced SM.
Learning Objectives
After completing this activity, the participant should be better able to:
- Describe the pathophysiology of nonadvanced SM, including the effects of driver mutations on MC activation and the rationale for new targeted therapies
- Assess symptoms and analyze laboratory and genetic testing results to differentially diagnose nonadvanced SM and classify subtype
- Discuss recent clinical trial evidence and regulatory status for new and emerging targeted treatment options, including selective tyrosine kinase inhibitors and their role in treating SM
- Formulate individualized treatment plans reflecting clinical evidence for treatment efficacy and safety, patient-reported outcomes, and shared decision making
Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact us prior to the live event at info@exchangecme.com.
Fee Information & Refund/Cancellation Policy
There is no fee for this program.
Register Now


18
2025
Interleukin-33 and Lower Tract Respiratory Diseases
Moving From Pathophysiology to Management
Time: | 6:30 PM-8:30 PM PT |
Venue: | Marriott Marquis San Francisco, Yerba Buena 7 (Lower B2 Level) |
Location: | San Francisco, CA |
Faculty: | Professor Tom Wilkinson MA Cantab MBBS PhD FRCP FERS; Professor Dave Singh MD, FERS, FBPhS; Jonathan M. Hand, MD |


18
2025
Interleukin-33 and Lower Tract Respiratory Diseases
Moving From Pathophysiology to Management
Time: | 7:00 PM-8:30 PM PT |
Venue: | Live Stream |
Location: | Live Stream |
Faculty: | Jonathan M. Hand, MD; Professor Dave Singh MD, FERS, FBPhS; Professor Tom Wilkinson MA Cantab MBBS PhD FRCP FERS |

19
2025
Turning the Tide on Eosinophilic Granulomatosis With Polyangiitis
New Targeted Strategies to Reduce Disease Burdens
Time: | 7:00 PM-8:30 PM PT |
Venue: | Live Stream |
Location: | Live Stream |
Faculty: | Michael E. Wechsler, MD, MMSc; Praveen Akuthota, MD; Anisha B. Dua, MD, MPH; Jason M. Springer, MD |

19
2025
Turning the Tide on Eosinophilic Granulomatosis With Polyangiitis
New Targeted Strategies to Reduce Disease Burdens
Time: | 6:30 PM-8:30 PM PT |
Venue: | Marriott Marquis San Francisco, Yerba Buena 7 (Lower B2 Level) |
Location: | San Francisco, CA |
Faculty: | Michael E. Wechsler, MD, MMSc; Praveen Akuthota, MD; Anisha B. Dua, MD, MPH; Jason M. Springer, MD |
